TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ventral Incisional Hernia Repair: Comparison Of Laparoscopic and Open Repair With Mesh
Brief Summary: The purpose of this research is to compare open ventral incisional hernia repair to the laparoscopic repair with respect to complications, recurrence, pain, return to normal activities of daily living, and return to work.


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Procedure: Open mesh repair of ventral incisional hernia, Procedure: Laparoscopic mesh repair of ventral incisional hernia | Intervention Type: PROCEDURE; Name: Open mesh repair of ventral incisional hernia; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Laparoscopic mesh repair of ventral incisional hernia; Assigned to Arm(s): 1
B: Arm Label: 0; Type: ACTIVE_COMPARATOR; Interventions: Procedure: laparoscopic correction of hernia with mesh | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: laparoscopic correction of hernia with mesh | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: laparoscopic correction of hernia with mesh | Intervention Type: PROCEDURE; Name: laparoscopic correction of hernia with mesh; Assigned to Arm(s): 0, 1, 2
C: Arm Label: 1: tacks; Type: ACTIVE_COMPARATOR; Interventions: Procedure: tack fixation of mesh | Arm Label: 2: glue; Type: EXPERIMENTAL; Interventions: Procedure: glue fixation of mesh | Intervention Type: PROCEDURE; Name: tack fixation of mesh; Assigned to Arm(s): 1: tacks | Intervention Type: PROCEDURE; Name: glue fixation of mesh; Assigned to Arm(s): 2: glue
D: Arm Label: fixation with Protack; Type: EXPERIMENTAL; Interventions: Procedure: laparoscopic ventral herniotomy, Device: Protack | Arm Label: fixation with Securestrap; Type: EXPERIMENTAL; Interventions: Procedure: laparoscopic ventral herniotomy, Device: Securestrap | Arm Label: fixation with Glubran; Type: EXPERIMENTAL; Interventions: Procedure: laparoscopic ventral herniotomy, Device: Glubran | Intervention Type: PROCEDURE; Name: laparoscopic ventral herniotomy; Assigned to Arm(s): fixation with Glubran, fixation with Protack, fixation with Securestrap | Intervention Type: DEVICE; Name: Protack; Assigned to Arm(s): fixation with Protack | Intervention Type: DEVICE; Name: Securestrap; Assigned to Arm(s): fixation with Securestrap | Intervention Type: DEVICE; Name: Glubran; Assigned to Arm(s): fixation with Glubran

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes Who Are Not Achieving Glycemic Targets
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of adding Symlin to an established regimen of insulin glargine in subjects with type 2 diabetes who are not achieving glycemic targets.


Options:
A: Arm Label: Saxagliptin, 5 mg + insulin; Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, 5 mg + insulin | Arm Label: Placebo + insulin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + insulin | Intervention Type: DRUG; Name: Saxagliptin, 5 mg + insulin; Assigned to Arm(s): Saxagliptin, 5 mg + insulin | Intervention Type: DRUG; Name: Placebo + insulin; Assigned to Arm(s): Placebo + insulin
B: Arm Label: Pramlintide; Type: ACTIVE_COMPARATOR; Interventions: Drug: pramlintide acetate | Intervention Type: DRUG; Name: pramlintide acetate; Assigned to Arm(s): Pramlintide
C: Arm Label: Pioglitazone QD; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Arm Label: Placebo QD; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo QD
D: Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 104-Week, Open-label, Multi-centre, Phase IIIb Study Evaluating the Effect of Treatment With Rosuvastatin 40 mg on Atherosclerotic Disease as Measured by Intravascular Ultrasound and Quantitative Coronary Angiography in Subjects Undergoing Coronary Angiography Who Have Coronary Artery Disease
Brief Summary: The purpose of this study is to see if 40 mg of rosuvastatin taken daily will reduce the atherosclerosis (fatty deposits) in your arteries


Options:
A: Arm Label: treatment; Type: EXPERIMENTAL; Interventions: Drug: Simvastatin | Arm Label: untreated; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): treatment
B: Intervention Type: DRUG; Name: Rosuvastatin calcium; Assigned to Arm(s): N/A
C: Arm Label: statin; Type: EXPERIMENTAL; Interventions: Drug: atorvastatin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): statin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Evaluate the Use of Rosuvastatin in Subjects On Regular Haemodialysis: an Assessment of Survival and Cardiovascular Events (AURORA). A Double Blind, Randomised, Phase 3b, Parallel-group Study to Compare the Effects of Rosuvastatin With Placebo on Assessment of Survival & Cardiovascular Events When Given to Subjects With End-stage Renal Failure on Chronic Haemodialysis Treatment
Brief Summary: The purpose of this study is to see if rosuvastatin helps to reduce the number of heart attacks, strokes and cardiovascular deaths in patients undergoing haemodialysis.


Options:
A: Arm Label: Rosuvastatin 10mg; Type: EXPERIMENTAL; Interventions: Drug: 10mg Rosuvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 10mg Rosuvastatin; Assigned to Arm(s): Rosuvastatin 10mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Conventional hemodialysis; Type: ACTIVE_COMPARATOR; Interventions: Device: Conventional hemodialysis | Arm Label: Frequent hemodialysis; Type: EXPERIMENTAL; Interventions: Device: Frequent hemodialysis | Intervention Type: DEVICE; Name: Conventional hemodialysis; Assigned to Arm(s): Conventional hemodialysis | Intervention Type: DEVICE; Name: Frequent hemodialysis; Assigned to Arm(s): Frequent hemodialysis
C: Arm Label: 1: low flux hemodialysis; Type: OTHER; Interventions: Procedure: low flux hemodialysis | Arm Label: 2 on-line hemodiafiltration; Type: ACTIVE_COMPARATOR; Interventions: Procedure: on-line hemodiafiltration | Intervention Type: PROCEDURE; Name: on-line hemodiafiltration; Assigned to Arm(s): 2 on-line hemodiafiltration | Intervention Type: PROCEDURE; Name: low flux hemodialysis; Assigned to Arm(s): 1: low flux hemodialysis
D: Arm Label: Low normal pH (arterial pH 7.36-7.38); Type: ACTIVE_COMPARATOR; Interventions: Drug: ammonium chloride or sodium citrate/citric acid | Arm Label: High Normal pH (arterial pH 7.44-7.46); Type: ACTIVE_COMPARATOR; Interventions: Drug: Sodium citrate/citratic acid | Intervention Type: DRUG; Name: ammonium chloride or sodium citrate/citric acid; Assigned to Arm(s): Low normal pH (arterial pH 7.36-7.38) | Intervention Type: DRUG; Name: Sodium citrate/citratic acid; Assigned to Arm(s): High Normal pH (arterial pH 7.44-7.46)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Double-dummy, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Comparison of 12-week Treatment of Two Doses (5 Mcg and 10 Mcg) of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler, Placebo and Ipratropium Bromide Inhalation Aerosol (MDI) i
Brief Summary: The primary objective was to compare the bronchodilator efficacy of two doses (5 mcg and 10 mcg) of tiotropium inhalation solution delivered by the Respimat inhaler once daily to placebo and to ipratropium bromide MDI four times daily in patients with COPD. The secondary objective was to compare the safety of tiotropium inhalation solution delivered by the Respimat to placebo and ipratropium bromide MDI.


Options:
A: Arm Label: FF/GW642444 Inhalation Powder 100/25 mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Powder 50mcg/25mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Powder 200/25 mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: GW642444 25mcg QD; Type: EXPERIMENTAL; Interventions: Drug: GW642444 Inhalation Powder | Intervention Type: DRUG; Name: FF/GW642444 Inhalation Powder; Assigned to Arm(s): FF/GW642444 Inhalation Powder 100/25 mcg QD, FF/GW642444 Inhalation Powder 200/25 mcg QD, FF/GW642444 Inhalation Powder 50mcg/25mcg QD | Intervention Type: DRUG; Name: GW642444 Inhalation Powder; Assigned to Arm(s): GW642444 25mcg QD
B: Arm Label: Tiotropium; Type: OTHER; Interventions: Drug: Tiotropium | Arm Label: Placebo; Type: OTHER; Interventions: Device: Respimat | Intervention Type: DEVICE; Name: Respimat; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium
C: Arm Label: Aclidinium 200 μg once-daily; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): Aclidinium 200 μg once-daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DEVICE; Name: 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Double-dummy, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Comparison of 12-week Treatment of Two Doses (5 Mcg and 10 Mcg) of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler, Placebo and Ipratropium Bromide Inhalation Aerosol (MDI) i
Brief Summary: The primary objective was to compare the bronchodilator efficacy of two doses (5 mcg and 10 mcg) of tiotropium inhalation solution delivered by the Respimat inhaler once daily to placebo and to ipratropium bromide MDI four times daily in patients with COPD. The secondary objective was to compare the safety of tiotropium inhalation solution delivered by the Respimat to placebo and ipratropium bromide MDI.


Options:
A: Intervention Type: DEVICE; Name: 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler; Assigned to Arm(s): N/A
B: Arm Label: Aclidinium 400 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 400 μg bid | Arm Label: Tiotropium 18 μg once-daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18 μg once-daily | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide 400 μg bid; Assigned to Arm(s): Aclidinium 400 μg bid | Intervention Type: DRUG; Name: Tiotropium 18 μg once-daily; Assigned to Arm(s): Tiotropium 18 μg once-daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DEVICE; Name: 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Tiotropium bromide; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Study Evaluating Acetaminophen Extended Release (3900 mg/Day) in the Treatment of Osteoarthritis of the Hip or Knee.
Brief Summary: The purpose of this study is to evaluate acetaminophen extended release (3900 mg/day) compared to placebo for safety and effectiveness in the relief of signs and symptoms of osteoarthritis of the hip or knee over 12 weeks


Options:
A: Intervention Type: DRUG; Name: Diclofenac sodium gel 1%; Assigned to Arm(s): N/A
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: acetaminophen extended release | Arm Label: 002; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: acetaminophen extended release; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 002
C: Arm Label: Tramadol Hydrochloride/Acetaminophen ER; Type: EXPERIMENTAL; Interventions: Drug: Tramadol HCl/Acetaminophen ER | Arm Label: Tramadol HCl/Acetaminophen IR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tramadol HCl/Acetaminophen IR | Intervention Type: DRUG; Name: Tramadol HCl/Acetaminophen ER; Assigned to Arm(s): Tramadol Hydrochloride/Acetaminophen ER | Intervention Type: DRUG; Name: Tramadol HCl/Acetaminophen IR; Assigned to Arm(s): Tramadol HCl/Acetaminophen IR
D: Arm Label: MEDIC; Type: ACTIVE_COMPARATOR; Interventions: Other: Neuromuscular training (NEMEX-TJR), Drug: Paracetamol, Drug: Burana, Drug: Pantoprazole, Behavioral: Dietary counseling, Behavioral: Patient education, Other: Insoles | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information | Intervention Type: OTHER; Name: Neuromuscular training (NEMEX-TJR); Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Information; Assigned to Arm(s): Standard treatment | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): MEDIC | Intervention Type: DRUG; Name: Burana; Assigned to Arm(s): MEDIC | Intervention Type: DRUG; Name: Pantoprazole; Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Dietary counseling; Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Patient education; Assigned to Arm(s): MEDIC | Intervention Type: OTHER; Name: Insoles; Assigned to Arm(s): MEDIC

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Testosterone Replacement for Older Men With Sarcopenia
Brief Summary: The purpose of this study is to determine whether testosterone replacement in older men with low testosterone levels will increase muscle strength, improve physical performance and overall sense of well being, and reduce fatigue.


Options:
A: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Drug: Topical testosterone gel 1% (active formulation) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Topical gel (placebo formulation) | Intervention Type: DRUG; Name: Topical testosterone gel 1% (active formulation); Assigned to Arm(s): Treatment | Intervention Type: DRUG; Name: Topical gel (placebo formulation); Assigned to Arm(s): Placebo
B: Arm Label: Energy Deficit; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sesame Oil | Arm Label: Energy Deficit + Testosterone; Type: EXPERIMENTAL; Interventions: Drug: testosterone enanthate | Intervention Type: DRUG; Name: Sesame Oil; Assigned to Arm(s): Energy Deficit | Intervention Type: DRUG; Name: testosterone enanthate; Assigned to Arm(s): Energy Deficit + Testosterone
C: Arm Label: Active Testosterone Gel; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil citrate (open label), Drug: Testosterone gel | Arm Label: Placebo Gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sildenafil citrate (open label), Other: Placebo gel | Intervention Type: DRUG; Name: Sildenafil citrate (open label); Assigned to Arm(s): Active Testosterone Gel, Placebo Gel | Intervention Type: DRUG; Name: Testosterone gel; Assigned to Arm(s): Active Testosterone Gel | Intervention Type: OTHER; Name: Placebo gel; Assigned to Arm(s): Placebo Gel
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Reandron 1000 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Reandron 1000; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double Blind, Double Dummy, Parallel Group, Active-Controlled Study To Evaluate The Effectiveness Of Morning Versus Evening Doses Of 320 Mg Valsartan Versus 40 Mg Lisinopril On The 24 Hour Blood Pressure Profile In Patients With Hypertension And Non-Insulin Dependent Diabetes
Brief Summary: A study comparing the antihypertensives Valsartan and Lisinporil when doses are in the morning and comparing a morning dose of Valsartan with an evening dose.


Options:
A: Intervention Type: DRUG; Name: valsartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lisinopril; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Any antihypertensive medication alone or in combination, Device: Ambulatory blood pressure monitoring | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Any antihypertensive medication alone or in combination, Device: Ambulatory blood pressure monitoring | Intervention Type: DRUG; Name: Any antihypertensive medication alone or in combination; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Any antihypertensive medication alone or in combination; Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: Ambulatory blood pressure monitoring; Assigned to Arm(s): 1, 2
C: Arm Label: Initial presentation of coronary disease - Stable angina; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - ACS; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - Coronary death; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - None; Type: N/A; Interventions: N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril, Device: ambulatory blood pressure monitoring | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril, Device: ambulatory blood pressure monitoring | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): 1, 2 | Intervention Type: DEVICE; Name: ambulatory blood pressure monitoring; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of High-volume Veno-venous Continuous Hemofiltration in the Early Management of Septic Shock Patients With Acute Renal Failure
Brief Summary: Sepsis and septic shock are still important causes of mortality in intensive care medicine. Renal replacement therapy by standard volume haemofiltration is currently used, but a higher-volume haemofiltration may improve the prognosis. The study is a prospective randomized multicenter trial comparing two treatments in patients suffering from septic shock complicated with acute renal failure admitted to ICU. One group will be treated by early high volume haemofiltration (70 ml/kg/h) and the second group by standard volume haemofiltration (35 ml/kg/h). The main outcome will be one-month mortality.


Options:
A: Arm Label: Intensive renal replacement therapy; Type: EXPERIMENTAL; Interventions: Procedure: renal replacement therapy | Arm Label: Less-intensive renal replacement therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: renal replacement therapy | Intervention Type: PROCEDURE; Name: renal replacement therapy; Assigned to Arm(s): Intensive renal replacement therapy, Less-intensive renal replacement therapy
B: Arm Label: High Volume; Type: EXPERIMENTAL; Interventions: Device: Venovenous haemofiltration (renal replacement therapy) | Arm Label: Medium Volume; Type: ACTIVE_COMPARATOR; Interventions: Device: Venovenous haemofiltration (renal replacement therapy) | Intervention Type: DEVICE; Name: Venovenous haemofiltration (renal replacement therapy); Assigned to Arm(s): High Volume | Intervention Type: DEVICE; Name: Venovenous haemofiltration (renal replacement therapy); Assigned to Arm(s): Medium Volume
C: Arm Label: Higher intensity CRRT regimen; Type: EXPERIMENTAL; Interventions: Procedure: "augmented" CRRT regimen | Arm Label: Lower intensity CRRT regimen; Type: ACTIVE_COMPARATOR; Interventions: Procedure: "augmented" CRRT regimen | Intervention Type: PROCEDURE; Name: "augmented" CRRT regimen; Assigned to Arm(s): Higher intensity CRRT regimen, Lower intensity CRRT regimen
D: Arm Label: high volume hemofiltration; Type: EXPERIMENTAL; Interventions: Procedure: high volume hemofiltration | Arm Label: standard care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard care | Intervention Type: PROCEDURE; Name: high volume hemofiltration; Assigned to Arm(s): high volume hemofiltration | Intervention Type: PROCEDURE; Name: standard care; Assigned to Arm(s): standard care

Answer: B